Tirzepatide: R&D Breakthrough and Clinical Value of the First-in-Class GIP/GLP-1 Dual Receptor Agonist

On May 13, 2022, an innovative drug named tirzepatide (brand name Mounjaro™) received its first U.S. approval, offering a new treatment option for glycemic control in adults with type 2 diabetes (T2D). Developed by Eli Lilly and Company, this GIP/GLP-1 dual receptor agonist has rapidly become a focal point in the field of metabolic disease treatment due to its unique mechanism of action, significant clinical efficacy, and broad development potential. This article provides a comprehensive analysis of the drug's core value and development prospects based on relevant research reports.

1. Core Drug Properties: Dual Receptor Synergy, a Novel Mechanism

Tirzepatide’s core advantage lies in its innovative "dual receptor agonism" mechanism. Both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones secreted by the intestine. The former is involved in nutrient and energy metabolism, while the latter delays gastric emptying, suppresses appetite, and enhances satiety. Together, they stimulate insulin secretion and reduce glucagon release. As a single molecule, tirzepatide efficiently activates both receptors, creating a synergistic effect. This not only leads to potent glycemic control but also results in significant weight loss, overcoming the limitations of traditional glucose-lowering drugs that typically target a single pathway.

Regarding administration, tirzepatide is given via subcutaneous injection once weekly, significantly improving patient convenience. The dosing regimen follows a clear stepwise escalation logic: the starting dose is 2.5 mg/week (for treatment initiation only, not primarily for glycemic effect), increased to 5 mg/week after 4 weeks. Subsequently, the dose can be increased in 2.5 mg increments every 4 weeks based on glycemic control needs, up to a maximum recommended dose of 15 mg/week. Injection sites can be the abdomen, thigh, or upper arm, and administration is not restricted by mealtime, further lowering the barrier to use. It is important to note that this drug is not indicated for type 1 diabetes, and studies have not been conducted in people with a history of pancreatitis, who should avoid its use.

2. Pharmacological Profile: Potent Glycemic Control + Weight Loss, Stable Pharmacokinetics

2.1 Pharmacodynamics: Dual Efficacy, Multidimensional Benefits

Tirzepatide is a 39-amino acid linear peptide. Acylation modification enables reversible albumin binding, extending its half-life to approximately 5 days, which provides the pharmacokinetic basis for once-weekly dosing. In people with T2D, it significantly enhances first- and second-phase insulin secretion, improves insulin sensitivity, reduces fasting and postprandial glucagon levels by 28% and 43% respectively, and effectively delays gastric emptying, reducing postprandial glucose excursions.

Beyond glycemic control, weight loss is another highlight of tirzepatide. In diet-induced obese mouse models, it reduces food intake and increases energy expenditure, thereby lowering and maintaining body weight. In human trials, significant weight loss has been observed in both people with diabetes and those with obesity/overweight without diabetes. This makes it particularly suitable for individuals with T2D and comorbid obesity. Additionally, the drug improves beta-cell function, optimizes lipid metabolism, and reduces levels of cardiovascular disease-related biomarkers, offering multidimensional health benefits.

2.2 Pharmacokinetics: Stable and Predictable, Wide Applicability

Tirzepatide's pharmacokinetic profile is stable and favorable. Following subcutaneous injection, the time to peak concentration is 8-72 hours, with an absolute bioavailability of 80%. Steady-state plasma concentrations are reached after 4 weeks of once-weekly dosing. It is widely distributed in the body, with a mean steady-state volume of distribution of approximately 10.3 L, and is 99% bound to plasma albumin. Metabolism occurs primarily via peptide hydrolysis, fatty acid beta-oxidation, and amide hydrolysis. Metabolites are excreted in urine and feces, with no detectable intact parent drug.

Notably, factors such as age, sex, race, body weight, and hepatic or renal impairment do not have a clinically meaningful impact on the pharmacokinetics of tirzepatide. This suggests good consistency in its safety and efficacy across diverse populations. However, it is important to note that because the drug delays gastric emptying, it may reduce the absorption of concurrently administered oral medications. For example, it significantly reduces the plasma concentration of oral contraceptives. Therefore, women using oral contraceptives should switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiating tirzepatide and after each dose escalation.

3. Clinical Trials: Data-Driven Efficacy, Outperforming Traditional Therapies

3.1 Type 2 Diabetes Treatment: Superior Glycemic Control and Weight Loss

In a series of Phase 3 SURPASS trials, tirzepatide was directly compared against placebo, semaglutide (a GLP-1 receptor agonist), insulin degludec, and insulin glargine, demonstrating overwhelming efficacy advantages.

In the monotherapy trial (SURPASS-1), involving 478 people with T2D inadequately controlled with diet and exercise alone, 40 weeks of treatment with different tirzepatide doses resulted in HbA1c reductions of 1.87% to 2.07%, compared to 0.04% for placebo. Notably, 87% to 92% of patients achieved an HbA1c target of <7%, far exceeding the 19% in the placebo group. Concurrently, mean body weight decreased by 7.0 to 9.5 kg, significantly better than the 0.7 kg reduction with placebo.

In combination therapy trials, tirzepatide's performance remained outstanding. Compared to semaglutide (SURPASS-2), the 5 mg, 10 mg, and 15 mg doses of tirzepatide achieved HbA1c reductions of 2.01%, 2.24%, and 2.30%, respectively, all superior to the 1.86% reduction with semaglutide. Weight loss (7.6 to 11.2 kg) was also significantly greater than that with semaglutide (5.7 kg).

Compared to insulin therapies (SURPASS-3, SURPASS-4), tirzepatide not only provided superior glycemic control but also led to weight loss, whereas insulin treatment was often associated with weight gain. Tirzepatide also reduced liver fat content and visceral adipose tissue volume, offering additional metabolic benefits. A dedicated trial in Japanese patients (SURPASS J-mono) confirmed that tirzepatide's glycemic efficacy was significantly superior to dulaglutide, with a maximum HbA1c reduction of 2.82%.

3.2 Obesity/Overweight Treatment: Marked Weight Loss with Metabolic Improvements

In the Phase 3 SURMOUNT-1 trial involving people with obesity or overweight without diabetes, tirzepatide demonstrated remarkable weight loss potential. After 72 weeks of treatment, the 5 mg, 10 mg, and 15 mg dose groups achieved mean weight reductions of 15.0%, 19.5%, and 20.9%, respectively, compared to 3.1% for placebo. A high proportion of patients (85% to 91%) achieved weight loss of ≥5%. Notably, 50% and 57% of patients in the 10 mg and 15 mg groups, respectively, achieved weight loss of ≥20%, far exceeding the 3% in the placebo group.

Beyond weight loss, tirzepatide improved cardiometabolic indicators in the obesity population, including reductions in waist circumference and systolic blood pressure, and optimization of fasting insulin and lipid levels. Assessment using the SF-36 health survey also indicated significant improvements in physical functioning, providing strong support for preventing obesity-related complications.

3.3 Safety and Adverse Events: Predominantly GI Reactions, Manageable Risks

The overall safety profile of tirzepatide is manageable. Adverse events are primarily gastrointestinal, exhibiting dose-dependency and tending to diminish over time.

In clinical trials for T2D, nausea (12%-18%), diarrhea (12%-17%), decreased appetite (5%-11%), and vomiting (5%-9%) were the most common adverse events, with an incidence of approximately 37.1% to 43.6%, higher than the 20.4% in the placebo group. Most reactions occurred during the dose-escalation period and diminished as treatment continued. Only 3.0% to 6.6% of patients discontinued due to severe gastrointestinal events.

In obesity trials, the incidence of GI events was slightly higher: nausea (24.6%-33.3%), diarrhea (18.7%-23.0%), constipation (11.7%-17.1%), vomiting (8.3%-12.2%). Nonetheless, the discontinuation rate remained controlled at 4.3% to 7.1%, indicating overall good tolerability.

Importantly, tirzepatide carries a boxed warning​ regarding the risk of thyroid C-cell tumors. Therefore, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Additionally, the drug may increase the risk of hypoglycemia (especially when combined with insulin or insulin secretagogues), hypersensitivity reactions, acute gallbladder disease, and pancreatitis. In patients with a history of diabetic retinopathy, clinicians should be vigilant for potential disease progression. Clinical use requires strict adherence to medical guidance and enhanced monitoring.

4. Development Journey and Future Directions: Multi-Pronged Strategy, Unlimited Potential

The development journey of tirzepatide has been clear and efficient: Phase I trials began in May 2016, marketing applications were submitted to the US, EU, and Japan in 2021, and U.S. FDA approval was secured in May 2022—completing the critical leap from early R&D to first approval in just 6 years.

Currently, tirzepatide's development pipeline extends far beyond T2D and obesity. Phase III trials are underway for cardiovascular disease associated with T2D (SURPASS-CVOT), heart failure, and pediatric/adolescent T2D (SURPASS-PEDS). A Phase II trial for non-alcoholic steatohepatitis (SYNERGY-NASH) is also in progress. Furthermore, its potential value in obstructive sleep apnea and reducing obesity-related mortality is being explored. As more clinical trial data emerge, tirzepatide has the potential to become a versatile agent covering a range of metabolic and cardiovascular diseases.

5. Summary

The first approval of tirzepatide marks the entry of metabolic disease treatment into a new era of "dual receptor agonism." Leveraging its innovative mechanism of activating both GIP and GLP-1 receptors, it achieves a dual breakthrough in "glycemic control + weight loss," with clinical efficacy significantly superior to traditional therapies. It also provides multidimensional benefits such as improved lipids and reduced visceral fat. Although gastrointestinal adverse events and specific contraindicated populations exist, the overall safety profile is manageable, and the once-weekly dosing regimen greatly enhances patient adherence.

From an R&D perspective, the indications for tirzepatide continue to expand. In the future, it holds promise for offering new hope to patients with conditions like heart failure and NASH. The success of this drug not only highlights the tremendous value of innovative drug development but also provides a novel approach for the comprehensive management of metabolic diseases, warranting high attention from both clinicians and patients.

Original Article：

Syed YY. Tirzepatide: First Approval. Drugs. 2022 Jul;82(11):1213-1220.